Beigene Ltd ADR (ONC) Stock Price, Quote & News

Company Profile

BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor o...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 61 685 19 00

Website: beonemedicines.com

Address:

Aeschengraben 27, 21st Floor, Basel, Switzerland

Crazyhorse6 Aug. 22 at 4:51 PM

$IBRX $AMGN $ONC WHEN?????

0 · Reply

MaverikIT Aug. 21 at 1:57 PM

@gpaisa $FUTU and younger bro $TIGR $ONC $LKNCY

0 · Reply

MaverikIT Aug. 18 at 2:06 PM

Eastern front$ $ONC $CWEEB $GDS $HSAI $TCOM $BABA

0 · Reply

TrendEdgeLogan Aug. 16 at 4:14 PM

$XBI $IBB $ONC $CNTA $ASND

1 · Reply

BixbyKnolls Aug. 15 at 11:36 PM

$IBRX Meanwhile - trial collaborator - $ONC hit another new high!

3 · Reply

Pika_Capital Aug. 15 at 4:25 PM

$ONC in dark mode this button looks pretty horrible. Just blank @michaelbozzello @StocktwitsHelp

0 · Reply

Pika_Capital Aug. 15 at 4:08 PM

$ONC onc is a no brainer here. Riding to $500

0 · Reply

MaverikIT Aug. 13 at 2:42 PM

@IsabellaDC @TheLongVol $DAVE & $LLY having party and going $NUTX $ONC $FUTU

0 · Reply

TheHookingBull Aug. 11 at 12:48 PM

$ONC potential china drug tarrifs impacting this price?

0 · Reply

Pika_Capital Aug. 8 at 2:30 PM

Exited $BHVN and buying $ONC $ASND since I needed cash to load up on these two puppies

0 · Reply

European Commission Approves Tablet Formulation of BeOne Medicines' BRUKINSA® for All Approved Indications

Aug 6, 2025, 1:36 PM EDT - 18 days ago

BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 6:00 AM EDT - 18 days ago

BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates

Aug 1, 2025, 8:31 AM EDT - 23 days ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Aug 1, 2025, 6:54 AM EDT - 23 days ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Jul 31, 2025, 6:00 AM EDT - 24 days ago

BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom's Macroglobulinemia

Jul 28, 2025, 6:00 AM EDT - 27 days ago

BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment

Jul 16, 2025, 6:00 AM EDT - 5 weeks ago

BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6

Jul 10, 2025, 6:00 AM EDT - 6 weeks ago

European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma

Jul 9, 2025, 8:00 PM EDT - 6 weeks ago

Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development

Jun 26, 2025, 6:00 AM EDT - 2 months ago

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

Jun 25, 2025, 6:00 AM EDT - 2 months ago

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

Jun 16, 2025, 11:06 AM EDT - 2 months ago

BeOne Medicines: Brukinsa Momentum And Pipeline Catalysts Justify Its Premium

Jun 12, 2025, 6:00 AM EDT - 2 months ago

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

Jun 11, 2025, 4:05 PM EDT - 2 months ago

U.S. FDA Approves Tablet Formulation of BeOne's BRUKINSA® for All Approved Indications

Jun 11, 2025, 6:01 AM EDT - 2 months ago

BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025

Jun 4, 2025, 7:08 AM EDT - 2 months ago

BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field

Jun 2, 2025, 6:00 AM EDT - 2 months ago

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

May 31, 2025, 8:00 AM EDT - 3 months ago

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA's Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

May 27, 2025, 8:30 AM EDT - 3 months ago

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

May 27, 2025, 6:00 AM EDT - 3 months ago

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer

May 22, 2025, 6:00 AM EDT - 3 months ago

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

May 14, 2025, 4:05 PM EDT - 3 months ago

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA's Leadership and Next-Generation Innovation

May 13, 2025, 6:01 AM EDT - 3 months ago

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

May 12, 2025, 1:05 PM EDT - 3 months ago

Undercovered Dozen: Richtech Robotics, Intesa Sanpaolo, BeiGene, Analog Devices +

ADI RR

May 8, 2025, 9:24 AM EDT - 3 months ago

BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit

May 7, 2025, 2:04 PM EDT - 3 months ago

BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript

May 7, 2025, 11:01 AM EDT - 3 months ago

Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat

May 7, 2025, 6:00 AM EDT - 3 months ago

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

Apr 29, 2025, 3:32 PM EDT - 4 months ago

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

Apr 17, 2025, 6:01 AM EDT - 4 months ago

BeiGene to Announce First Quarter 2025 Financial Results on May 7

Apr 3, 2025, 11:19 AM EDT - 5 months ago

BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit

Apr 3, 2025, 6:00 AM EDT - 5 months ago

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

Mar 31, 2025, 6:00 AM EDT - 5 months ago

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Mar 4, 2025, 8:37 AM EST - 6 months ago

China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer

Mar 4, 2025, 6:00 AM EST - 6 months ago

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

Feb 28, 2025, 2:00 PM EST - 6 months ago

BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025

Feb 27, 2025, 10:24 AM EST - 6 months ago

BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 6:00 AM EST - 6 months ago

BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Feb 25, 2025, 6:01 AM EST - 6 months ago

BeiGene to Present at Upcoming Investor Conferences

Feb 13, 2025, 6:01 AM EST - 6 months ago

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27

Feb 11, 2025, 8:00 AM EST - 6 months ago

BostonGene Collaborates with BeiGene to Advance Biomarker Discovery in Mantle Cell Lymphoma

Jan 22, 2025, 12:29 PM EST - 7 months ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN COGT JAZZ XBI ZYME

Jan 6, 2025, 2:00 AM EST - 8 months ago

BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe

Dec 27, 2024, 6:00 AM EST - 8 months ago

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

Dec 23, 2024, 6:00 AM EST - 8 months ago

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 12, 2024, 7:30 PM EST - 9 months ago

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

Dec 9, 2024, 8:30 PM EST - 9 months ago

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

Dec 4, 2024, 6:00 AM EST - 9 months ago

BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL

Dec 2, 2024, 6:01 AM EST - 9 months ago

BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024

Crazyhorse6 Aug. 22 at 4:51 PM

$IBRX $AMGN $ONC WHEN?????

0 · Reply

MaverikIT Aug. 21 at 1:57 PM

@gpaisa $FUTU and younger bro $TIGR $ONC $LKNCY

0 · Reply

MaverikIT Aug. 18 at 2:06 PM

Eastern front$ $ONC $CWEEB $GDS $HSAI $TCOM $BABA

0 · Reply

TrendEdgeLogan Aug. 16 at 4:14 PM

$XBI $IBB $ONC $CNTA $ASND

1 · Reply

BixbyKnolls Aug. 15 at 11:36 PM

$IBRX Meanwhile - trial collaborator - $ONC hit another new high!

3 · Reply

Pika_Capital Aug. 15 at 4:25 PM

$ONC in dark mode this button looks pretty horrible. Just blank @michaelbozzello @StocktwitsHelp

0 · Reply

Pika_Capital Aug. 15 at 4:08 PM

$ONC onc is a no brainer here. Riding to $500

0 · Reply

MaverikIT Aug. 13 at 2:42 PM

@IsabellaDC @TheLongVol $DAVE & $LLY having party and going $NUTX $ONC $FUTU

0 · Reply

TheHookingBull Aug. 11 at 12:48 PM

$ONC potential china drug tarrifs impacting this price?

0 · Reply

Pika_Capital Aug. 8 at 2:30 PM

Exited $BHVN and buying $ONC $ASND since I needed cash to load up on these two puppies

0 · Reply

Pika_Capital Aug. 7 at 4:50 PM

$ONC I'm back. Put money from zlab in here. These guys have been executing flawlessly.

0 · Reply

JarvisFlow Aug. 7 at 2:42 PM

RBC Capital has adjusted their stance on BeOne Medicines ( $ONC ), setting the rating to Outperform with a target price of 349 → 364.

0 · Reply

JarvisFlow Aug. 7 at 2:25 PM

Guggenheim has updated their rating for BeOne Medicines ( $ONC ) to Buy with a price target of 365.

0 · Reply

Estimize Aug. 6 at 10:12 PM

$ONC reported 0.91 EPS and 1,315 revenue for Q2. http://www.estimize.com/intro/onc?chart=historical&metric_name=eps&utm_content=ONC&utm_med

0 · Reply

TheHookingBull Aug. 6 at 2:30 PM

$ONC so now we get to have lower drug prices overhang worries for the foreseeable future 🙄

0 · Reply

d_risk Aug. 6 at 1:21 PM

$ONC - BeiGene, Ltd. - 10Q - Updated Risk Factors ONC’s 10-Q reveals expanded risks on financing, patent protection, manufacturing, drug pricing, regulatory compliance, geopolitical tensions, counterfeit drugs, clinical safety issues, IT security, environmental laws, global operations, China regulatory complexities, shareholder rights under Swiss jurisdiction, and potential impacts from climate change and AI use. #Pharmaceuticals #ClinicalSafety #PatentProtection #GeopoliticalRisks #RegulatoryCompliance 🟢 Added 🟠 Removed https://d-risk.ai/ONC/10-Q/2025-08-06

0 · Reply

mikesterz7 Aug. 6 at 12:09 PM

$ONC Total Revenue: Increased 42% to $1.3 billion compared to Q2 2024. Global BRUKINSA Revenue: Increased 49% to $950 million compared to Q2 2024. Diluted GAAP Earnings per American Depositary Share (ADS): $0.84. Non-GAAP Diluted Earnings per ADS: $2.25. GAAP Net Income: $94 million, a $215 million increase over the prior year.

0 · Reply

Olddrache Aug. 5 at 5:12 PM

$ONC Expected move 7.3%

1 · Reply

jegade Aug. 5 at 5:08 PM

$ONC what is the move here @Olddrache

0 · Reply

MaverikIT Aug. 4 at 1:52 PM

@IsabellaDC $FUTU $SE $ONC $CWEB ... All east young men

0 · Reply

TrendEdgeLogan Aug. 1 at 6:25 PM

If you're not looking at biotech stocks today idk what you are looking at. $XBI $IBB $ONC $CNTA $ASND KNSA, MIRM, ALNY, SPRY, XERS

0 · Reply

moneymarker20188 Jul. 31 at 1:51 PM

$ONC market maker will take out short at $6S

0 · Reply

Market Cap	23.65B
Revenue (ttm)	3.81B
Net Income (ttm)	-644.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	318.72
Profit Margin	-16.92%
Debt to Equity Ratio	0.05

Volume	189,200
Avg Vol	468,388
Day's Range	N/A - N/A
Shares Out	99.25M
Stochastic %K	82%
Beta	0.35
Analysts	Strong Sell
Price Target	$321.39